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The 2011 World Health Organization global report on HIV and/or AIDS estimated that 
sub-Saharan Africa comprised 67% of the global HIV burden, with a current estimate 
of 5.9 million cases in South Africa. Since the introduction of antiretroviral therapy, 
there has been an increase in the incidence of non-AIDS-defining cancers. Gestational 
trophoblastic neoplasm (GTN) is a rare pregnancy-related disorder with an incidence 
ranging from 0.12–0.7/1000 pregnancies in Western nations. The overall cure rate is 
about 90%. Response to treatment for GTN is generally favourable; but the sequelae of 
HIV and/or AIDS, the resultant low CD4 counts, comorbidities, poor performance status 
and the extent of metastatic disease in patients receiving chemotherapy, compromise the 
prognosis and survival.
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Introduction
Infection with the human immune deficiency virus (HIV) in sub-Saharan Africa affected an 
estimated 22.5 million people, of whom 5.9 million were in South Africa, however, in the recent 
2014 UNAIDS progress report, for the first time since 2009, a 17% decline was reported in the rate 
of newly diagnosed HIV cases for women of reproductive age, living in sub-Saharan Africa.1 May 
et al. found that, between 1996 and 2008, the life expectancy of people receiving antiretroviral 
therapy (ART) had increased by an average of 15 years.2 People with HIV infection live longer 
as a result of ART, and consequently are at risk of developing illnesses associated with ageing, 
chronic illnesses and malignancies.
Kaposi’s sarcoma (KS), non-Hodgkin’s lymphoma (NHL) and cervical cancer are the most 
observed AIDS-defining cancers. In the era of ART, a significant decrease in the incidence of AIDS-
defining illnesses has been observed, whilst non-AIDS cancers (NADCs) are on the increase. An 
estimated 30% – 40% of HIV-infected patients are likely to develop a cancer during the duration 
of their disease.3 An increased incidence was observed for anal, lung, certain head and neck 
cancers, and hepatocellular carcinoma, as well as Hodgkin’s disease, whilst no increased risk 
was observed for breast, prostate and colorectal cancer in the HIV-positive cohort. No clearly 
established association between HIV and/or AIDS and gestational trophoblastic neoplasm 
(GTN) exists. Data from the Swiss HIV Cohort Study showed that 19% of all cohort deaths in the 
ART area were attributable to NADCs.4
GTN is a rare pregnancy-related disorder that derives from placental tissue and is clinically 
diagnosed if the B-HCG level fails to decrease or normalise in women when a normal pregnancy 
is excluded, and collectively includes: invasive mole, choriocarcinoma and placental site 
trophoblastic tumour (PSTT) that can lead to death if left untreated. Potential risk factors for the 
development of GTN include a history of a previous molar pregnancy, partial mole (0.5% risk) 
and a complete mole (15% risk), maternal age and a post-evacuation, persistent raised B-HCG 
level. Management includes careful dilatation and curettage (D&C), and the need for systemic 
treatment is guided by the International Federation of Gynecology and Obstetrics (FIGO)/WHO 
score that predicts if either single agent or combination chemotherapy is required. GTN is now 
one of the most curable solid tumours, with cure rates of more than 90% even in the presence 
of metastatic disease.5,6 The occurrence of malignancy amongst people living with HIV and/or 
AIDS represents a management challenge. We present here two choriocarcinoma case studies of 
women with HIV and/or AIDS.
Ethics approval
The Human Research Ethics Committee (HREC) of Stellenbosch University approved the present 
report.
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Case presentation
Case 1
A 33-year-old woman (gravida 5, para 2, miscarriage 3) 
presented post-evacuation for a miscarriage with persistent 
vaginal bleeding and a raised B-HCG value. She was 
living with HIV and/or AIDS and had been established 
on ART for one year. Clinical examination confirmed an 
abdominal uterine mass of 22 weeks’ gestation with a foul-
smelling vaginal discharge. Staging examinations included a 
computed tomography (CT) scan of the lungs, abdomen and 
pelvis and confirmed several bilateral lung metastases and an 
extensive tumour that involved the uterus and extended into 
the anterior abdominal wall (Figure 1). Abnormal laboratory 
studies revealed haemoglobin 4 g% (12.5 g% – 15 g%),a serum 
B-HCG level of 115 544 IU/L (<5 IU/L), and CD4 count of 290 
cells/µL, (500 cells/µL – 2010 cells/µL). She was diagnosed 
as having a FIGO Stage III:12 high-risk choriocarcinoma.
Management included continuation with ART (tenofovir, 
efavirenz and lamivudine), intravenous antibiotics (piper-
acillin and amikacin), and low-dose chemotherapy with 
the alternating regime of methotrexate 50 mg alternative 
days (D1, 3, 5, 7) with leucovorin rescue. She completed 
one cycle without any adverse effects. However, a week 
post-chemotherapy she developed a neutropaenic fever. 
Abnormal laboratory studies then confirmed serum-
creatinine 10.7 mmol/L (2.1 mmol/L – 7.1 mmol/L), urea 
151 µmol/L (49 µmol/L – 90 µmol/L), and a pancytopaenia: 
white blood cells 0.13 × 109/L (4.00–10.00 × 109/L), haemoglobin 
6.6 g%, and platelets 15 × 109/L (178–400 × 109/L). A follow-up 
CD4 count decreased to 29 cells/µL and the B-HCG value 
decreased to 50 296 IU/L. Supportive management included 
granulocyte-stimulating factor (G-CSF) and intravenous 
antibiotics according to the sensitivity of a positive blood 
culture (Klebsiella pneumonia). A vaginal pus swab cultured 
Candida species.
The outcome for the patient was unfortunate as she died 
owing to severe neutropaenic sepsis from a resistant 
Klebsiella and Candida sepsis that resulted in acute renal 
failure and severe immune suppression.
Case 2
A 20-year-old woman (gravida 2, para 0, miscarriage 1) 
presented with a history of haemoptysis, grade IV dyspnoea 
and a raised B-HCG level. She was known to have had 
a previous molar pregnancy, diagnosed three years 
previously. On clinical examination, symptoms and signs of 
thyrotoxicosis were present. Staging examinations included 
a lung CT that confirmed numerous bilateral, diffuse soft-
tissue nodules throughout both lung fields in keeping with 
metastatic disease (Figure 2). Abnormal laboratory studies 
revealed a B-HCG value >898 400 IU/L (<5 IU/L), T4: 
47 pmol/L (10.3 pmol/L – 21.9 pmol/L), and a CD4 count of 
200 cells/µL (500 cells/µL – 2010 cells/µL); a HIV enzyme-
linked immunosorbent assay (ELISA) test was positive. 
Direct microscopy for acid-fast bacilli was negative. She was 
diagnosed with a FIGO Stage III:15 high-risk choriocarcinoma 
in a newly diagnosed HIV-positive patient.
Management included commencement with ART (tenofovir, 
efavirenz and lamivudine) with the addition of trimetroprim-
sulfamethoxazole for Pneumocystis jiroveci prophylaxis (PCP) 
as her CD4+ count was ≤200 cells/μL, intravenous antibiotic 
(clindamycin) and acute thyrotoxicosis therapy consisting of 
carbimazole and propranolol. Low-dose chemotherapy with 
methotrexate 50 mg alternated with leucovorin rescue on days 
1, 3, 5 and 7 was initiated. However, she required admission 
into a high-care facility when spontaneous breathing became 
Source: Department of Clinical Oncology, Tygerberg Hospital
FIGURE 1: Computer tomographic scan of the abdomen demonstrating a grossly 
enlarged uterus and tumour mass extending through the anterior abdominal 
wall to the subcutaneous tissue.
Source: Department of Clinical Oncology, Tygerberg Hospital
FIGURE 2: Computer tomographic scan of the lung demonstrating bilateral 
diffuse soft-tissue nodules in keeping with metastatic disease. Note the large 
cavitating lesion in the left lower lobe, found in metastases from choriocarcinoma 
and resulting from tumour haemorrhage.
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problematic and a continuous positive airway pressure 
(CPAP) support system was needed. A standard blood culture 
confirmed Gram-positive cocci and a coagulase negative 
staphylococcal organism was isolated sensitive to vancomycin. 
A urine specimen cultured positive for Candida albicans.
When severe oxygen decompensation occurred, she was 
admitted to the ICU facility and intubation was necessitated. 
She died secondary to poor performance status, severe 
immune suppression, metastatic choriocarcinoma and a 
Staphylococcus and Candida sepsis when she developed 
acute respiratory distress syndrome (ARDS).
Discussion
Malignancy tends to occur at a younger age in people 
living with HIV and/or AIDS, and presents with atypical 
presentations, widespread metastatic disease, and aggressive 
tumour behaviour. In patients with immunodeficiency, 
physiological principles for the development of malignancy 
exist: (1) the lack of autoimmune surveillance, (2) an imbalance 
between cellular differentiation and proliferation and (3) a 
repeat antigenic stimulation by an oncogenic virus leads to 
the emergence and proliferation of abnormal cells. Amongst 
HIV-infected individuals, a 30% – 40% increase in the 
incidence of NADCs has been observed, and this contributes 
to morbidity and mortality in HIV-infected patients, now 
that survival is prolonged with the use of ART.3,7
Established chemotherapy regimens have resulted in a 
favourable response to GTN, and more than 90% of cases 
will be cured. Choriocarcinoma is generally associated with 
pregnancy but an estimated 25% occur after miscarriage, 25% 
after term pregnancy and the rest after a molar pregnancy. 
Choriocarcinoma is an aggressive form of GTN owing to 
its rapid growth and metastatic potential. In women, a high 
index of suspicion is needed to make a diagnosis based on an 
unexplained high B-HCG level in the presence of metastases 
in the lung, liver or brain. A high HCG level can also cause 
thyrotoxicosis. Delay in diagnosis with delay in starting 
chemotherapy treatment is a common cause of early death in 
patients with metastasis.6
Using the WHO/FIGO scoring system, patients are grouped 
into low- and high-risk categories. High-risk patients 
require combination chemotherapy as they are unlikely to 
be cured with a single agent. In high-risk patients, 50% of 
deaths occur within the first four weeks of initial treatment. 
Early deaths are attributed to respiratory compromise, 
haemorrhage secondary to a heavy tumour burden within 
the thorax, and rapid tumour destruction associated with 
full-dose chemotherapy treatment. Intubation in patients 
with very poor respiratory function should be avoided as 
far as possible as high ventilator pressures might trigger 
fatal intrapulmonary haemorrhage owing to friable tumour 
vasculature; and hence the introduction of low-dose therapy 
in the initial treatment of high-risk patients to gradually 
reduce tumour volume and significantly reduce the risk of 
haemorrhage to minimise the risk of early death.8,9
Because of extensive comorbidities, low-CD4 counts, poor 
performance status and the extent of metastatic disease, both 
our patients were offered initial low-dose chemotherapy 
to debulk tumour load. In the first case study, our patient 
developed post-chemotherapy neutropaenic sepsis. The 
outcome for her resulted in death secondary to a poor 
performance, severe immune suppression (CD4 count 
decrease from 290 cells/µL to 29 cells/µL), neutropaenic 
sepsis and extensive metastatic choriocarcinoma that 
resulted in acute renal failure. In the second case, the 
patient experienced severe oxygen desaturation owing to 
extensive lung metastases that necessitated intubation and 
ICU admission. The outcome for her was dismal as she died 
secondary to a poor performance status, severe immune 
suppression, sepsis and extensive metastatic choriocarcinoma 
when she developed ARDS.
Both our patients experienced severe immune suppression, 
had extensive metastatic disease and developed associated 
post-chemotherapy neutropaenia that increased their 
susceptibility to developing severe and fatal infections. Our 
cases also highlight previous findings of reported studies 
on GTN and HIV that confirm an associated poor outcome 
related to chemotherapy in women with HIV and/or AIDS if 
they present with low CD4 counts, have a poor performance 
status and an associated poor tolerance to chemotherapy 
treatment.10,11
Conclusion
Response to GTN is generally favourable with cure rates in 
excess of 90%. However, in patients with advanced immune 
suppression, medical management of non-AIDS-defining 
cancers can be compromised owing to their extent and 
aggressive tumour behaviour with associated treatment-
related complications.
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